News | May 27, 2021
Sun Pharma Q4 FY21 net profit up 124%
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
The antibody cocktail is to be administered for the treatment of mild to moderate COVID-19
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
We focused on developing the product last year but now our focus is on ramping up our manufacturing capacity
Natco has withdrawn its application filed with the Indian Patent Office, seeking Compulsory License against Lilly for Baricitinib for Covid-19 in India
Number of approved manufacturing sites of Remdesivir in the country has increased from 22 sites to 60
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
Dr. Reddy's has the rights to distribute 250mn doses in India
Subscribe To Our Newsletter & Stay Updated
